Pharmacokinetics and bioavailability of intravenous and oral chlordesmethyldiazepam in humans

Eur J Clin Pharmacol. 1988;34(1):109-12. doi: 10.1007/BF01061430.

Abstract

Six healthy, fasting volunteers were given single doses of chlordesmethyldiazepam by 1 mg i.v., or as drops or tablets. Chlordesmethyldiazepam and its metabolite, lorazepam, in multiple plasma samples and in urine collected for 120 h after each dose were determined by electron-capture GLC. Mean kinetic variables for intravenous chlordesmethyldiazepam were: volume of distribution, 1.71 l.kg-1; elimination half-life, 113 h; total clearance, 0.21 ml.min-1.kg-1; cumulative excretion of lorazepam glucuronide 24.2% of the dose. Following a lag time of 15.5 min (tablets) and 4.2 min (drops), which were significantly different, the absorption of oral chlordesmethyldiazepam was a first order process, with apparent absorption half-life values averaging 1.5 h (tablets) and 1.1 h (drops). Bioavailability was 77% for tablets and 79% for drops.

Publication types

  • Clinical Trial
  • Comparative Study
  • Controlled Clinical Trial

MeSH terms

  • Absorption
  • Administration, Oral
  • Adult
  • Anti-Anxiety Agents / administration & dosage
  • Anti-Anxiety Agents / pharmacokinetics*
  • Anticonvulsants / administration & dosage
  • Anticonvulsants / blood
  • Anticonvulsants / pharmacokinetics
  • Anticonvulsants / urine
  • Benzodiazepines*
  • Biological Availability
  • Diazepam / analogs & derivatives*
  • Half-Life
  • Humans
  • Injections, Intravenous
  • Male
  • Nordazepam / administration & dosage
  • Nordazepam / analogs & derivatives*
  • Nordazepam / blood
  • Nordazepam / pharmacokinetics
  • Nordazepam / urine
  • Random Allocation
  • Tablets
  • Time Factors

Substances

  • Anti-Anxiety Agents
  • Anticonvulsants
  • Tablets
  • Benzodiazepines
  • Nordazepam
  • chlordesmethyldiazepam
  • Diazepam